by Alyson Lam | Mar 17, 2025 | UK
Background of Supplementary Protection Certificates (SPCs) SPCs are heavily relied on by pharmaceutical companies to extend the period of patent protection. Under the current regulations, SPCs can only be granted if the product is: 1) protected by a basic patent in...
by Luke Pettit | Jan 2, 2025 | EPO
Background and First Instance Decisions In Europe, claims directed toward mathematical methods are allowable only if it is clear that they contribute to the “technical character” of an invention. Under European practice, to assess the inventive step of a mathematical...
by David Eyre | Dec 6, 2024 | Uncategorised
Haemophilia B A blot clot is produced following a cascade of reactions after injury. Haemophilia is a disorder of blood clotting whereby one of the factors that contributes to this cascade of reactions is defective. Consequently, for sufferers from this condition...
by Chloe Sullivan | Nov 14, 2024 | UPC
Background The multi-territory dispute between NanoString and 10x Genomics, which has been ongoing in the US and Europe for quite some time, was expanded to the Unified Patent Court soon after it opened its doors in June last year. The battle before the UPC began in...
by David Eyre | Sep 16, 2024 | US & International
Background For valuable inventions it is relatively typical for a US patent to be expanded into a family of patent rights. Naturally, the value of patents is further enhanced by extra patent term. Patents with expiry dates beyond the normal 20 year period can be...
Recent Comments